XML 194 R49.htm IDEA: XBRL DOCUMENT
v3.25.2

Operating Segments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Operating Segments [Abstract] |
Schedule of Operating Segments | The Group’s CODM is the CEO of the Company.
|  | Year ended December 31, 2024 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 1,306 |  |  | $ | 1,306 |
Total |  |  | - |  |  |  | 1,306 |  |  |  | 1,306 |
Segment loss (gain) |  |  | 4,873 |  |  |  | 2,443 |  |  |  | 7,316 |
Equity losses from the investment in MitoCareX |  |  |  |  |  |  |  |  |  |  | 429 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (259 | )
Tax income |  |  |  |  |  |  |  |  |  |  | (14 | )
Loss |  |  |  |  |  |  |  |  |  |  | 7,472 |
|  | Year ended December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 2,879 |  |  | $ | 2,879 |
Total |  |  | - |  |  |  | 2,879 |  |  |  | 2,879 |
Segment loss (gain) |  |  | 5,359 |  |  |  | 1,456 |  |  |  | 6,815 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 210 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (1,164 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 22 |
Loss |  |  |  |  |  |  |  |  |  |  | 5,883 |
|  | Year ended December 31, 2022 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 1,347 |  |  | $ | 1,347 |
Total |  |  | - |  |  |  | 1,347 |  |  |  | 1,347 |
Segment loss |  |  | 8,405 |  |  |  | (118 | ) |  |  | 8,287 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 109 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (5,818 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 14 |
Loss |  |  |  |  |  |  |  |  |  |  | 2,592 |
|  | As of December 31, 2024 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 8,407 |  |  | $ | 1,764 |  |  | $ | 10,171 |
Segment Liabilities |  | $ | 1,194 |  |  | $ | 226 |  |  | $ | 1,420 |
|  | As of December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 7,069 |  |  | $ | 4,113 |  |  | $ | 11,182 |
Segment Liabilities |  | $ | 1,441 |  |  | $ | 154 |  |  | $ | 1,595 |

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | sprcy_OperatingSegmentsTablesLineItems
Namespace Prefix: | sprcy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration